BridgeBio Pharma (BBIO) Leases (2020 - 2025)
Historic Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $6.6 million.
- BridgeBio Pharma's Leases rose 177.05% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 177.05%. This contributed to the annual value of $5.8 million for FY2024, which is 2815.5% down from last year.
- Latest data reveals that BridgeBio Pharma reported Leases of $6.6 million as of Q3 2025, which was up 177.05% from $6.2 million recorded in Q2 2025.
- BridgeBio Pharma's Leases' 5-year high stood at $17.1 million during Q3 2021, with a 5-year trough of $5.8 million in Q4 2024.
- Over the past 5 years, BridgeBio Pharma's median Leases value was $9.8 million (recorded in 2023), while the average stood at $10.3 million.
- As far as peak fluctuations go, BridgeBio Pharma's Leases skyrocketed by 7739.53% in 2021, and later crashed by 3287.23% in 2022.
- BridgeBio Pharma's Leases (Quarter) stood at $15.9 million in 2021, then tumbled by 32.87% to $10.7 million in 2022, then dropped by 24.83% to $8.0 million in 2023, then dropped by 28.15% to $5.8 million in 2024, then rose by 13.63% to $6.6 million in 2025.
- Its Leases was $6.6 million in Q3 2025, compared to $6.2 million in Q2 2025 and $7.2 million in Q1 2025.